Evidence map›Paper›PMID 40676448›Full record

ArticleDrug delivery and translational research2025

Intranasal delivery of engineered anti-SARS-CoV-2 extracellular vesicles therapeutically represses lung infection and inflammation.

Adi Idris, Surya Shrivastava, Wenqing Gao, Aroon Supramaniam, Yaman Tayyar, Nicholas P West, Gabrielle Kelly, Dhruba Acharya, Nigel A J McMillan, Kevin V Morris

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adi Idris *Institute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia. a2.idris@qut.edu.au.ORCID 0000-0002-0562-1549
Surya Shrivastava *Center for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute, Duarte, CA, USA.
Wenqing Gao *Centre for Immunology and Infection Control, School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Aroon SupramaniamInstitute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia.
Yaman TayyarInstitute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia.
Nicholas P WestInstitute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia.
Gabrielle KellyInstitute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia.
Dhruba AcharyaInstitute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia.
Nigel A J McMillanInstitute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia.
Kevin V MorrisCentre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Kelvin Grove, Brisbane, QLD, Australia.

Funding

Cell-derived extracellular vesicle mediated epigenetic silencing of HIV in the brainR01MH134389 · NIMH · GEORGE MASON UNIVERSITY · PI Fatah Kashanchi · 2023 to 2026
$2.0M
NIMH NIH HHS R01 MH134389
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are amenable to genetic engineering in that EVs can be endowed with surface armaments that can directly bind to target molecules or receptors. We previously developed HEK293 cell-derived EVs that contain a novel fusion tetraspanin protein, CD63, embedded within a highly conserved anti-SARS-CoV-2 nanobody, VHH72. These anti-SARS-CoV-2-enriched EVs bind SARS-CoV-2 spike protein and can functionally neutralize SARS-CoV-2 in vitro. Here, we extend our observations in vivo using EVs derived from neural stem cells (NSCs) and demonstrated the antiviral effectiveness of these direct-acting EVs in the lungs of SARS-CoV-2 infected mice when administered intranasally post-infection. Using NanoString-based immune transcriptomics we showed that these EVs exert mild anti-inflammatory effects on SARS-CoV-2 infected lungs. This is the first demonstration of the effective use of intranasally delivered EVs ladened with anti-SARS-CoV-2 nanobodies in vivo.

Indexed as

COVID-19COVID-19 Drug TreatmentExtracellular VesiclesSARS-CoV-2Single-Domain AntibodiesAdministration, IntranasalAnimalsHEK293 CellsHumansInflammationLungMiceSpike Glycoprotein, CoronavirusSingle-Domain AntibodiesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Extracellular vesiclesNeural stem cellSARS-CoV-2Spike proteinVHH72

Identifiers

PMID40676448
PMCPMC12507999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.